Professor Annemieke Geluk is a distinguished leader in the field of immunodiagnostics for mycobacterial infectious diseases at the Leiden University Medical Center. She holds the position of Professor of Immunodiagnostics of Mycobacterial Infectious Diseases within the LUCID Research division and serves as Head of Immunodiagnostics of Mycobacterial Diseases. Following her Master's degree in Chemistry from both the University of Leiden and the University of Virginia in Charlottesville, she earned her PhD in Immunology from the Leiden University Medical Center. Her academic career has been dedicated to advancing diagnostic methodologies for complex infectious diseases with significant global health implications.
Professor Geluk's pioneering research has significantly advanced the development of immunodiagnostic tools for tuberculosis and leprosy, two devastating mycobacterial diseases affecting millions worldwide. Her work focuses on creating reliable diagnostic approaches that can identify these infections at early stages, directly improving patient outcomes and public health interventions. Through leadership of her research group, she has established innovative frameworks that bridge laboratory discoveries with practical clinical applications in near-patient settings. Her contributions have been instrumental in developing accessible diagnostic methods deployable in resource-limited regions where these diseases remain endemic.
Beyond her research achievements, Professor Geluk maintains a prominent role in international scientific networks including the VALIDATE consortium, which advances vaccine development and evaluation for infectious diseases. She actively mentors emerging scientists and clinicians while fostering interdisciplinary collaborations across immunology, microbiology, and clinical medicine. Her leadership extends to shaping research agendas in mycobacterial disease diagnostics with a strong emphasis on translating scientific discoveries into practical healthcare solutions. Currently, her laboratory continues to innovate in diagnostic technologies that integrate advanced immunological insights with clinical applications to combat tuberculosis and leprosy more effectively on a global scale.
